HIGHLIGHTS
- who: Claudia Valenzuela from the (UNIVERSITY) have published the research: Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme, in the Journal: (JOURNAL)
- what: While the treatment landscape of IPF is growing increasingly favourable, many challenges and unmet needs remain.
- how: This review describes how the nintedanib clinical programme has helped to address some of these challenges.
- future: Future directions Emerging therapeutic strategies Research into improved treatment options for patients with IPF continues. Directions for future research namely emerging therapeutic options precision medicine and other progressive fibrosing interstitial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.